drugset / Trial / NCT01509755
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes
Summary
This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.
Timeline
- Start
- 2000-10
- Primary completion
- 2001-10
- Completion
- 2001-10
Publications
- Results Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004 Jun;27(6):1335-42. doi: 10.2337/diacare.27.6.1335.
- Results Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Glimepiride | Small molecule | — | Oral |
| Subject | Liraglutide | Peptide | 0.045 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.225 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.45 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.6 mg | Subcutaneous |
| Subject | Liraglutide | Peptide | 0.75 mg | Subcutaneous |